Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. Sandborn WJ, et al. Among authors: colombel jf. Gastroenterology. 2020 Jun;158(8):2123-2138.e8. doi: 10.1053/j.gastro.2020.01.047. Epub 2020 Feb 8. Gastroenterology. 2020. PMID: 32044319 Free article. Clinical Trial.
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soulé JC, Galmiche JP, Lerebours E, Descos L, Viteau JM, et al. Gendre JP, et al. Among authors: colombel jf. Gastroenterology. 1993 Feb;104(2):435-9. doi: 10.1016/0016-5085(93)90411-5. Gastroenterology. 1993. PMID: 8425685 Clinical Trial.
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soulé JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaïche J, Mary JY. Modigliani R, et al. Among authors: colombel jf. Gastroenterology. 1996 Mar;110(3):688-93. doi: 10.1053/gast.1996.v110.pm8608877. Gastroenterology. 1996. PMID: 8608877 Clinical Trial.
Clinical characteristics of Crohn's disease in 72 families.
Colombel JF, Grandbastien B, Gower-Rousseau C, Plegat S, Evrard JP, Dupas JL, Gendre JP, Modigliani R, Bélaïche J, Hostein J, Hugot JP, van Kruiningen H, Cortot A. Colombel JF, et al. Gastroenterology. 1996 Sep;111(3):604-7. doi: 10.1053/gast.1996.v111.pm8780563. Gastroenterology. 1996. PMID: 8780563
Methotrexate in Crohn's disease: long-term efficacy and toxicity.
Lémann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF. Lémann M, et al. Among authors: colombel jf. Am J Gastroenterol. 2000 Jul;95(7):1730-4. doi: 10.1111/j.1572-0241.2000.02190.x. Am J Gastroenterol. 2000. PMID: 10925976 Clinical Trial.
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.
Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P; BMBF Competence Network "Inflammatory Bowel disease". Schreiber S, et al. Among authors: colombel jf. Int J Colorectal Dis. 2001 Feb;16(1):1-11; discussion 12-3. doi: 10.1007/s003840100285. Int J Colorectal Dis. 2001. PMID: 11317691
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Sandborn WJ, et al. Among authors: colombel jf. Inflamm Bowel Dis. 2001 Aug;7(3):192-201. doi: 10.1097/00054725-200108000-00003. Inflamm Bowel Dis. 2001. PMID: 11515844
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Among authors: colombel jf. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.
Management of Crohn's disease of the ileoanal pouch with infliximab.
Colombel JF, Ricart E, Loftus EV Jr, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Colombel JF, et al. Am J Gastroenterol. 2003 Oct;98(10):2239-44. doi: 10.1111/j.1572-0241.2003.07675.x. Am J Gastroenterol. 2003. PMID: 14572574
1,124 results